Aquestive Therapeutics, Inc. (AQST)
$
6.44
+0.29 (4.50%)
Key metrics
Financial statements
Free cash flow per share
-0.5036
Market cap
615.7 Million
Price to sales ratio
13.9514
Debt to equity
-1.7393
Current ratio
3.5293
Income quality
0.7639
Average inventory
7.7 Million
ROE
1.0881
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Aquestive Therapeutics, Inc. is a pharmaceutical company that specializes in identifying, developing, and commercializing innovative products to meet unmet medical needs both in the United States and internationally. The company has seen an interest income of $3,437,000.00 showcasing its financial investments. Its total costs and expenses amount to $88,332,000.00 reflecting the overall spending while the cost of revenue is $17,872,000.00 which highlights its production and operational expenses. Additionally, the company reported selling, general, and administrative expenses of $50,180,000.00 indicating its operational overhead costs. The weighted average number of diluted shares outstanding is $86,726,211.00 revealing potential dilution effects on shareholders. Among its marketed products are Sympazan, a clobazam treatment for Lennox-Gastaut syndrome, and Suboxone, a sublingual film for opioid dependence. Other products include Zuplenz, designed for nausea and vomiting related to chemotherapy, and Azstarys, a once-daily treatment for ADHD. The company's proprietary pipeline features Libervant, a buccal formulation of diazepam for seizures, and Exservan, a film formulation of riluzole for ALS. Additionally, it is developing AQST-108 and AQST-305, both sublingual film formulations targeting various health conditions, and KYNMOBI for Parkinson’s disease management. The stock is affordable at $5.67 making it suitable for budget-conscious investors. With a high average trading volume of 3,184,659.00 the stock indicates strong liquidity, attracting interest from various traders. Currently, the company's market capitalization stands at $639,534,736.00 classifying it as a small-cap player within the market. As a key player in the Drug Manufacturers - Specialty & Generic industry, Aquestive Therapeutics contributes significantly to the overall market landscape while driving innovation and growth within the Healthcare sector. This dynamic positioning underscores the company's commitment to addressing critical health challenges and expanding its presence in the pharmaceutical market.
Is Aquestive Therapeutics, Inc. (AQST) a good investment?
Investing in Aquestive Therapeutics, Inc. (AQST) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Aquestive Therapeutics, Inc. (AQST)'s stock forecast?
Analysts predict Aquestive Therapeutics, Inc. stock to fluctuate between $2.12 (low) and $7.55 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Aquestive Therapeutics, Inc.'s market capitalization?
As of 2025-12-04, Aquestive Therapeutics, Inc.'s market cap is $639,534,736, based on 99,306,636 outstanding shares.
How does Aquestive Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Aquestive Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Aquestive Therapeutics, Inc. (AQST) stock?
To buy Aquestive Therapeutics, Inc. (AQST) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for AQST. Place an order (Market, Limit, etc.).
What is the best time to invest in Aquestive Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Aquestive Therapeutics, Inc. perform in the last earnings report?
Revenue: $57,561,000 | EPS: -$0.51 | Growth: 292.31%.
Where can I find Aquestive Therapeutics, Inc.'s investor relations reports?
Visit https://www.aquestive.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Aquestive Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Aquestive Therapeutics, Inc. stock?
All-time high: $7.55 (2025-10-20) | All-time low: $0.62 (2022-07-01).
What are the key trends affecting Aquestive Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Aquestive Therapeutics, Inc. ( AQST ) Discusses Anaphylm Regulatory Progress, Commercial Strategy, and Pipeline Development November 6, 2025 12:00 PM EST Company Participants Daniel Barber - CEO, President & Director Melina Cioffi - Senior Vice President of Regulatory Affairs Cassie Jung - Chief Operating Officer Gary Slatko - Interim Chief Medical Officer Sherry Korczynski - Chief Commercial Officer Ernie Toth - Chief Financial Officer Conference Call Participants David Amsellem - Piper Sandler & Co., Research Division Presentation David Amsellem Piper Sandler & Co., Research Division All right. Well, good afternoon, everyone.
seekingalpha.com
Aquestive Therapeutics, Inc. ( AQST ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Daniel Barber - CEO, President & Director Ernie Toth - Chief Financial Officer Sherry Korczynski - Chief Commercial Officer Gary Slatko - Interim Chief Medical Officer Conference Call Participants Brian Korb David Amsellem - Piper Sandler & Co., Research Division Rick Miller - Cantor Fitzgerald & Co., Research Division Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Andreas Argyrides - Oppenheimer & Co. Inc., Research Division François Brisebois - LifeSci Capital, LLC, Research Division Jason Butler - Citizens JMP Securities, LLC, Research Division Denis Reznik - Raymond James & Associates, Inc., Research Division James Molloy - Alliance Global Partners, Research Division Presentation Operator Good day, and thank you for standing by.
zacks.com
Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.13 per share a year ago.
zacks.com
Here is how Aquestive Therapeutics (AQST) and Arcturus Therapeutics (ARCT) have performed compared to their sector so far this year.
seekingalpha.com
Aquestive Therapeutics leverages its PharmFilm® platform to develop Anaphylm, a sublingual epinephrine film targeting a $1B+ U.S. market. AQST's management, including former EpiPen marketing leadership, and a recent $85M equity raise position the company for a strong commercial launch. Base case projections see Anaphylm capturing 15–25% market share, supporting an $8–$20 per-share valuation if launch and adoption succeed.
zacks.com
Aquestive Therapeutics (AQST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
seekingalpha.com
Aquestive Therapeutics's Anaphylm could be the first FDA-approved, non-invasive, orally delivered epinephrine for anaphylaxis, with a PDUFA date set for January 2026. FDA's decision not to convene an advisory committee is a positive signal, and clinical data seems to strongly support Anaphylm's safety and efficacy. If approved, Anaphylm could capture significant market share, potentially driving Aquestive's valuation above $1bn and offering >50% upside for investors.
zacks.com
Aquestive Therapeutics shares surge after FDA skips advisory meeting on Anaphylm NDA, keeping its January 2026 action date intact.
zacks.com
Here is how Aquestive Therapeutics (AQST) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
globenewswire.com
WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the pricing of an underwritten offering of 21,250,000 shares of its common stock at an offering price of $4.00 per share. The gross proceeds of the offering to Aquestive, before deducting the underwriting discounts and commissions and other offering expenses payable by Aquestive, are expected to be $85 million. The Company intends to use the net proceeds received from the offering, together with the Company's existing cash and cash equivalents, primarily to advance the launch and commercialization of Anaphylm™ (epinephrine) Sublingual Film for the treatment of severe life-threatening allergic reactions, including anaphylaxis, assuming United States Food and Drug Administration (FDA) approval, and for working capital, capital expenditures and general corporate purposes. All of the securities are to be sold by the Company. The offering is expected to close on or about August 15, 2025, subject to satisfaction of customary closing conditions.
See all news
